Evidence map›Paper›PMID 41607407›Full record

ArticleFrontiers in neuroscience2025

Correction: An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease.

Christopher L Reading, Jiayan Yan, Marcia A Testa, Donald C Simonson, Hira Javaid, Lisa Schmunk, Daniel E Martin-Herranz, Robert Brooke, Juozas Gordevicius, Jeffrey Zhang and 7 more

Abstract readPublished Erratum
In one paragraph

Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Christopher L ReadingBioVie Inc., Carson City, NV, United States.
Jiayan YanBioVie Inc., Carson City, NV, United States.
Marcia A TestaDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, United States.
Donald C SimonsonDivision of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Hira JavaidHurdle.bio/Chronomics Ltd., London, United Kingdom.
Lisa SchmunkHurdle.bio/Chronomics Ltd., London, United Kingdom.
Daniel E Martin-HerranzHurdle.bio/Chronomics Ltd., London, United Kingdom.
Robert BrookeEpigenetic Clock Development Foundation, Torrance, CA, United States.
Juozas GordeviciusEpigenetic Clock Development Foundation, Torrance, CA, United States.
Jeffrey ZhangPrinceton Pharmatech, Princeton, NJ, United States.
Harvey YuanPrinceton Pharmatech, Princeton, NJ, United States.
Clarence AhlemBioVie Inc., Carson City, NV, United States.
Lixia WangBioVie Inc., Carson City, NV, United States.
Penelope MarkhamBioVie Inc., Carson City, NV, United States.
Nily OsmanBioVie Inc., Carson City, NV, United States.
Stephen O'QuinnBioVie Inc., Carson City, NV, United States.
Joseph PalumboBioVie Inc., Carson City, NV, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fnins.2025.1516746.].

Indexed as

agingAlzheimer'sbezisterimcognitiondementiaDNA methylationinsulinneuroinflammation

Identifiers

PMID41607407
PMCPMC12835768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.